Accelerated precision oncology

Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s unprecedented patient selection method represents a paradigm change in precision oncology drug development. Powered by our AP3 platform, we match drug mechanisms to the biologic drivers of cancer in patients, uncovering drug sensitivity not achievable through genomics.

Committed to delivering real therapeutic outcomes for patients

Aiming to address the world’s most common and pressing cancers, Acrivon’s technology and pipeline is built to improve patient outcomes.

This is possible due to our unique OncoSignature® patient selection test, which is designed to accurately match our therapeutics with patients to ensure they will truly benefit from our treatments.

Our pipeline

Our pipeline is initially focused on DNA Damage Response, cell cycle, and transcriptional regulators.

Our lead program, ACR-368 (also known as Prexasertib, in-licensed from Lilly), is a clinically-advanced, second-generation kinase inhibitor of the DNA Damage Response. Currently in phase 2 clinical development, ACR-368 has demonstrated durable single agent activity, including complete responses, in a proportion of patients and a favorable safety profile across multiple high unmet need solid cancer types.

Our two preclinical, internally-developed pipeline programs target critical nodes involved in the replication stress response and cell cycle regulation.

Partnering with Acrivon

Impactful therapeutics matched to the right patients

Our AP3 platform uniquely enables Acrivon to develop in-licensed, internally developed, and partnered therapeutics in patient selection trials for accelerated approval pathway. We continually assess in-licensing and partnering opportunities with like-minded visionary companies.

Founded & led by accomplished drug developers

Our global team operates out of two leading life science clusters, Greater Boston and Medicon Valley in Southern Scandinavia. Our experienced Scientific and Management Team includes leading pioneers in phosphoproteomics, and executives with extensive experience in precision oncology therapeutic and protein-based companion diagnostic development.

Peter Blume-Jensen

M.D., Ph.D. CEO, President, Founder
  • Three decades precision oncology R&D and in-licensing leadership experience
  • Expertise in oncogenic kinase signaling, phosphoproteomics, and clinical drug and biomarker development
  • Executive Serono, Merck & Co., Daiichi Sankyo; CSO Metamark Genetics
  • First marketed prostate test ProMark® (NCCN Guidelines)
  • Inventor AP3 platform and OncoSignature® patient selection method

Erick Gamelin

M.D., Ph.D. Chief Medical Officer
  • 30 years academic (Professor Medical Oncology) & industry leadership
  • Previously CMO STEP Pharma
  • Senior clinical roles Amgen, Pfizer, Dynavax, and Macrogenics
  • Formerly CEO, The West Oncology Institute, a national university cancer center and hospital
  • Led >150 phase 1-3 oncology trials
  • Awarded “Chevalier in the National Order of Merit” by the French Minister of Health

Kristina Masson

Ph.D. Site Head, SVP Operations, Co-Founder
  • Expertise in cancer biology, predictive biomarkers, novel therapeutics development
  • Founder, President, and CEO of OncoSignature (acquired by Acrivon)
  • Establishment and leadership of Acrivon’s phosphoproteomic hub and early drug programs based on company’s proprietary AP3 platform
  • Previously cross-functional team lead at Merrimack Pharmaceuticals
  • Post-Doc MIT/Broad
  • OncoSignature® trademark protection and brand identity

Jeremy Barton

M.D. Chief Medical Advisor
  • Three decades clinical oncology drug development experience
  • Previously CMO Mirati Therapeutics, Effector, and Biogen-Idec
  • Previously Head Early Oncology Drug Development Pfizer overseeing all oncology compounds through IND to POC; Chair of PFE Technical Review Committee
  • Lead 4 INDs, supervised 10 INDs, co-led commercialization of 3 marketed products

Jesper Olsen

Ph.D. Professor, University of Copenhagen, Academic Co-Founder, Head of Phosphoproteomics
  • Professor quantitative proteomics, University of Copenhagen
  • Vice Director, Novo Nordisk Foundation Center for Protein Research
  • Pioneer in mass spectrometry-based phosphoproteomics for analyses of cell-signaling networks at systems-wide scale
  • Comprehensive kinase drug profilings with clinical actionability
  • Amongst most cited phosphoproteomics experts; top 0.1% in protein sciences

Eric Devroe

Ph.D. SVP Business Operations
  • Expertise in launching, building, operationally leading, and executing in life sciences companies
  • Founder and CEO, Xione Therapeutics and Opsonix
  • Previously Exec. Dir., Strategic Alliances, MD Anderson Cancer Center; VP, BD, Metamark Genetics
  • EIR, Wyss Institute at Harvard
  • Venture Associate, Flagship Pioneering

Michail Shipitsin

Ph.D. Sr. Director, Head of Clinical Biomarker Development
  • Over 15 years expertise in translational and clinical biomarker research and development
  • Pioneer of automated, digital multiplex imaging and clinical biomarker tests
  • Previously, Dir, Head, Biomarker Development, Metamark Genetics and XTuit Pharmaceuticals
  • Post-Doc DFCI
  • Scientific lead on first-of-a-kind marketed, automated quantitative prognostic prostate cancer test, ProMark®

Mary Rose Keller

VP, Clinical Operations
  • Over 4 decades Global Clinical Research and Development Operations leadership
  • Previously Director, Clinical Research Programs, the Cancer Research Institute, UC Davis and UCSF
  • Led >400 clinical programs and teams in pharma industry
  • Numerous approved NDA submissions
  • VP at Heron Therapeutics, Tocagen, Prometheus, and Sequenom
  • Global Head, VP clinical operations at Shire and Pfizer

Peter Blume-Jensen

M.D., Ph.D. CEO, President, Founder
  • Three decades precision oncology R&D and in-licensing leadership experience
  • Expertise in oncogenic kinase signaling, phosphoproteomics, and clinical drug and biomarker development
  • Executive Serono, Merck & Co., Daiichi Sankyo; CSO Metamark Genetics
  • First marketed prostate test ProMark® (NCCN Guidelines)
  • Inventor AP3 platform and OncoSignature® patient selection method

Erick Gamelin

M.D., Ph.D. Chief Medical Officer
  • 30 years academic (Professor Medical Oncology) & industry leadership
  • Previously CMO STEP Pharma
  • Senior clinical roles Amgen, Pfizer, Dynavax, and Macrogenics
  • Formerly CEO, The West Oncology Institute, a national university cancer center and hospital
  • Led >150 phase 1-3 oncology trials
  • Awarded “Chevalier in the National Order of Merit” by the French Minister of Health

Kristina Masson

Ph.D. Site Head, SVP Operations, Co-Founder
  • Expertise in cancer biology, predictive biomarkers, novel therapeutics development
  • Founder, President, and CEO of OncoSignature (acquired by Acrivon)
  • Establishment and leadership of Acrivon’s phosphoproteomic hub and early drug programs based on company’s proprietary AP3 platform
  • Previously cross-functional team lead at Merrimack Pharmaceuticals
  • Post-Doc MIT/Broad
  • OncoSignature® trademark protection and brand identity

Jeremy Barton

M.D. Chief Medical Advisor
  • Three decades clinical oncology drug development experience
  • Previously CMO Mirati Therapeutics, Effector, and Biogen-Idec
  • Previously Head Early Oncology Drug Development Pfizer overseeing all oncology compounds through IND to POC; Chair of PFE Technical Review Committee
  • Lead 4 INDs, supervised 10 INDs, co-led commercialization of 3 marketed products

Jesper Olsen

Ph.D. Professor, University of Copenhagen, Academic Co-Founder, Head of Phosphoproteomics
  • Professor quantitative proteomics, University of Copenhagen
  • Vice Director, Novo Nordisk Foundation Center for Protein Research
  • Pioneer in mass spectrometry-based phosphoproteomics for analyses of cell-signaling networks at systems-wide scale
  • Comprehensive kinase drug profilings with clinical actionability
  • Amongst most cited phosphoproteomics experts; top 0.1% in protein sciences

Eric Devroe

Ph.D. SVP Business Operations
  • Expertise in launching, building, operationally leading, and executing in life sciences companies
  • Founder and CEO, Xione Therapeutics and Opsonix
  • Previously Exec. Dir., Strategic Alliances, MD Anderson Cancer Center; VP, BD, Metamark Genetics
  • EIR, Wyss Institute at Harvard
  • Venture Associate, Flagship Pioneering

Michail Shipitsin

Ph.D. Sr. Director, Head of Clinical Biomarker Development
  • Over 15 years expertise in translational and clinical biomarker research and development
  • Pioneer of automated, digital multiplex imaging and clinical biomarker tests
  • Previously, Dir, Head, Biomarker Development, Metamark Genetics and XTuit Pharmaceuticals
  • Post-Doc DFCI
  • Scientific lead on first-of-a-kind marketed, automated quantitative prognostic prostate cancer test, ProMark®

Mary Rose Keller

VP, Clinical Operations
  • Over 4 decades Global Clinical Research and Development Operations leadership
  • Previously Director, Clinical Research Programs, the Cancer Research Institute, UC Davis and UCSF
  • Led >400 clinical programs and teams in pharma industry
  • Numerous approved NDA submissions
  • VP at Heron Therapeutics, Tocagen, Prometheus, and Sequenom
  • Global Head, VP clinical operations at Shire and Pfizer

Backed by top-tier investors